Market Overview

Benzinga's Top Downgrades

Share:
Benzinga's Top Downgrades
Related NVS
Juno Therapeutics Viewed As A Sympathy Play On Kite Pharma's KTE-C19
vTv Therapeutics Shares Initiated With Buy Rating, $13 Target
Amgen's erenumab (AMG 334) successful in late-stage study in migraine prevention (Seeking Alpha)
Related ZIOP
Watch These 5 Huge Put Purchases In Friday Trade
Mid-Afternoon Market Update: Guess? Jumps On Earnings Beat; Signet Jewelers Shares Tumble

Analysts at Deutsche Bank downgraded Novartis AG (NYSE: NVS) from “buy” to “hold.” Novartis' shares closed at $63.20 yesterday. Novartis' trailing-twelve-month ROA is 6.24%.

Analysts at Jefferies downgraded ZIOPHARM Oncology (NASDAQ: ZIOP) from “buy” to “hold.” ZIOPHARM's shares closed at $4.44 yesterday. ZIOPHARM's trailing-twelve-month ROE is -110.59%.

Analysts at Wells Fargo downgraded Stifel Financial (NYSE: SF) from “market perform” to “underperform.” Stifel Financial's shares closed at $31.45 yesterday. Stifel Financial's PEG ratio is 0.81.

Brean Capital downgraded IDEX (NYSE: IEX) from “buy” to “hold.” IDEX's shares closed at $45.98 yesterday. IDEX's trailing-twelve-month profit margin is 10.50%.

Latest Ratings for NVS

DateFirmActionFromTo
Sep 2016Chardan CapitalInitiates Coverage onBuy
Apr 2016Morgan StanleyDowngradesEqual-weightUnderperform
Apr 2016Argus Capital Initiates Coverage onHold

View More Analyst Ratings for NVS
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (IEX + NVS)

View Comments and Join the Discussion!